Logo for Fennec Pharmaceuticals Inc

Fennec Pharmaceuticals Investor Relations Material

Latest events

Logo for Fennec Pharmaceuticals Inc

Q1 2025

Fennec Pharmaceuticals
Logo for Fennec Pharmaceuticals

Q1 2025

13 May, 2025
Logo for Fennec Pharmaceuticals

Q4 2024

10 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies

Latest reports from Fennec Pharmaceuticals Inc

Access all reports
Fennec Pharmaceuticals Inc. is a specialized biopharmaceutical company primarily focused on developing treatments aimed at preventing ototoxicity (hearing loss) caused by platinum-based chemotherapy in pediatric cancer patients. Its flagship product, PEDMARK, represents a formulation of sodium thiosulfate designed to mitigate this side effect, catering to a niche yet critical aspect of pediatric oncology care. The company is headquartered in Research Triangle Park, North Carolina, and its shares are listed on the Nasdaq.